Secuencia óptima del tratamiento del CCRm: ¿Cuál es el papel del panitumumab?.

17 / 31

Sensitivity to 2nd-line therapy
Considerations for sequencing anti-EGFR
vs anti-VEGF mAb therapy in mCRC
Wainberg ZA, Drakaki A. Expert Opin Biol Ther 2015; Zaniboni A, Fornica V. Cancer Chemother Phalmacol 2016
Tumour shrinkage
• Anti-EGFR-resistant cells may remain sensitive to anti-VEGF mAb therapy*
whereas anti-VEGF-resistant cells may become simultaneously resistant to
anti-EGFR therapy†
• Tumour cells are less (epi)genetically stable than stromal cells so it may be
preferable to use tumour cell-targeted drugs (e.g. anti-EGFR mAb) early